PEPTONIC medical (publ) progress towards next clinical study
- -
PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and appointed A+ Science AB as
Read MorePEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and appointed A+ Science AB as
Read MoreIdag noteras PEPTONIC Medical på AktieTorget och i samband med det har VD, Dan Markusson, intervjuats av Redeye. Titta på intervjun » Aktiens handelsbeteckning är PMED. Aktiens ISIN-kod är SE0005962206.
Read More
Recent Comments